Deborah Gurgel Smith1, John Anthony Vanchiere2, Michelle Raley3, Andrew David Yurochko4, Mohammad Alfrad Nobel Bhuiyan5, Kevin Sean Murnane6, Rona Scott4, Jeremy Kamil4, Jill Rush-Kolodzey1, Martha Whyte7, Kenneth Densmore3, Maarten Van Diest3, Christopher Kevil8. 1. Department of Public Health, Louisiana State University Health Shreveport, Shreveport, LA, USA. 2. Department of Pediatrics and Department of Infectious Diseases, Louisiana State University Health Shreveport, Shreveport, LA, U.S.A. 3. Center of Excellence for Emerging Viral Threats, Louisiana State University Health Shreveport, Louisiana, U.S.A. 4. Department of Microbiology and Immunology, Louisiana State University Health Shreveport, Shreveport, LA, U.S.A. 5. Department of Medicine, Louisiana State University Health Shreveport, Louisiana, U.S.A. 6. Department of Pharmacology, Toxicology & Neuroscience, Department of Psychiatry, Louisiana State University Health Shreveport, Louisiana, U.S.A. 7. Louisiana Office of Public Health, Shreveport, Louisiana, U.S.A. 8. Department of Pathology and Translational Pathobiology, Louisiana State University Health Shreveport, Louisiana, U.S.A.
Abstract
Background: Vaccinating susceptible populations quickly and safely is vital during a pandemic. Mass vaccination programs using a drive-through method have been shown to reach large numbers of people efficiently during vaccine campaigns. Methods: We performed a quantitative, cross-sectional study analyzing data collected by the COVID-19 mass vaccination program conducted by Louisiana State University Health Shreveport (LSUSH). Results: Between December 2020 and September 2021, the vaccination program administered 90,655 COVID-19 vaccines. Among those who received at least the first dose of the vaccine, there were 21,700 men and 28,269 women; 22,820 were ≥60 years of age; 28,031 identified as Caucasian, 19,249 as African American, 47,916 as non-Hispanic, and most of them reported that they had not tested positive for COVID-19 before vaccination. Discussion: The LSUHS vaccination center served people from different regions within Louisiana as well as those from outside Louisiana. Vaccination is a crucial public health measure in the fight against the COVID-19 pandemic. Conclusions: Our study showed that the mass vaccination program conducted by LSUHS had a considerable positive impact on communities in Northwest Louisiana. This drive-through method is an effective strategy with which to reach a significant number of people during a pandemic.
Background: Vaccinating susceptible populations quickly and safely is vital during a pandemic. Mass vaccination programs using a drive-through method have been shown to reach large numbers of people efficiently during vaccine campaigns. Methods: We performed a quantitative, cross-sectional study analyzing data collected by the COVID-19 mass vaccination program conducted by Louisiana State University Health Shreveport (LSUSH). Results: Between December 2020 and September 2021, the vaccination program administered 90,655 COVID-19 vaccines. Among those who received at least the first dose of the vaccine, there were 21,700 men and 28,269 women; 22,820 were ≥60 years of age; 28,031 identified as Caucasian, 19,249 as African American, 47,916 as non-Hispanic, and most of them reported that they had not tested positive for COVID-19 before vaccination. Discussion: The LSUHS vaccination center served people from different regions within Louisiana as well as those from outside Louisiana. Vaccination is a crucial public health measure in the fight against the COVID-19 pandemic. Conclusions: Our study showed that the mass vaccination program conducted by LSUHS had a considerable positive impact on communities in Northwest Louisiana. This drive-through method is an effective strategy with which to reach a significant number of people during a pandemic.
Entities:
Keywords:
COVID-19; Coronavirus; Drive-through; Mass vaccination; Vaccines
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Lacey J McIntosh; Max P Rosen; Kriti Mittal; Giles F Whalen; Venu G Bathini; Tasneem Ali; Kathryn L Edmiston; William V Walsh; Jonathan M Gerber Journal: Cancer Treat Rev Date: 2021-05-11 Impact factor: 12.111
Authors: Sara E Oliver; Julia W Gargano; Mona Marin; Megan Wallace; Kathryn G Curran; Mary Chamberland; Nancy McClung; Doug Campos-Outcalt; Rebecca L Morgan; Sarah Mbaeyi; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Kathleen Dooling Journal: MMWR Morb Mortal Wkly Rep Date: 2020-12-18 Impact factor: 17.586
Authors: Sara E Oliver; Julia W Gargano; Mona Marin; Megan Wallace; Kathryn G Curran; Mary Chamberland; Nancy McClung; Doug Campos-Outcalt; Rebecca L Morgan; Sarah Mbaeyi; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Kathleen Dooling Journal: MMWR Morb Mortal Wkly Rep Date: 2021-01-01 Impact factor: 35.301